Strategic Partnerships IMI actively pursues collaborations with global players in pharma and medical services, evidenced by recent deals with Grifols and Kiro Grifols. This presents an opportunity to position IMI as a preferred supplier for secure drug delivery devices to Grifols’ network and related supply chains.

Market Expansion The company has demonstrated growth through partnerships in specialized distribution channels and move into home health markets via IMS, signaling openness to channel-based sales and adjacent markets beyond traditional hospital settings.

Regulatory Readiness With ISO 13485:2003 and Medical Devices Directive 93/42/EEC certifications in place, IMI can pursue global sales opportunities with confidence in regulatory compliance, reducing onboarding time for new customers in regulated environments.

Security and Compliance As a leader in tamper evident technologies for IV syringes and delivery systems, IMI’s value proposition aligns with customers prioritizing medication safety and traceability, making a strong pitch for hospitals, clinics, and compounding centers seeking robust containment solutions.

Scale and Capabilities A U.S.-based manufacturer with 51-200 employees and a revenue range of 10–25 million signals potential for scalable, domestic supply, favorable for national distributors and group purchasing organizations seeking reliable, high-assurance suppliers.